CDTX Stock Price, Cidara Therapeutics Inc Quote, Chart

Market Summary

USD12.63-0.37

Delayed

-2.85%

CDTX Stock Price

View Fullscreen

CDTX RSI Chart

CDTX Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-50.25

Price/Sales (Trailing)

18.03

EV/EBITDA

-28.85

Price/Free Cashflow

-50.24

CDTX Price/Sales (Trailing)

CDTX Profitability

EBT Margin

-60.72%

Return on Equity

279.31%

Return on Assets

-34.21%

Free Cashflow Yield

-1.99%

CDTX Fundamentals

CDTX Revenue

Revenue (TTM)

63.9M

Rev. Growth (Yr)

72.06%

Rev. Growth (Qtr)

38.25%

CDTX Earnings

Earnings (TTM)

-22.9M

Earnings Growth (Yr)

58.05%

Earnings Growth (Qtr)

31.34%

Breaking Down CDTX Revenue

Last 7 days

-7.3%

Last 30 days

1403.6%

Last 90 days

1785.1%

Trailing 12 Months

1114.4%

How does CDTX drawdown profile look like?

CDTX Financial Health

Current Ratio

0.9

CDTX Investor Care

Shares Dilution (1Y)

1926.89%

Diluted EPS (TTM)

-0.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	83.2M	84.6M	56.5M	63.9M
2022	54.3M	27.6M	61.3M	64.3M
2021	11.9M	41.4M	46.1M	49.6M
2020	23.9M	26.8M	10.2M	12.1M
2019	0	0	0	20.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cidara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	tari leslie	acquired	-	-	111,250	chief scientific officer
Mar 15, 2024	sandison taylor	acquired	-	-	128,750	chief medical officer
Mar 15, 2024	ward shane	acquired	-	-	120,000	coo & clo
Mar 15, 2024	shah preetam	acquired	-	-	108,750	cfo & cbo
Mar 11, 2024	shah preetam	sold	-12,680	0.6698	-18,931	cfo & cbo
Mar 11, 2024	tari leslie	sold	-14,085	0.6698	-21,029	chief scientific officer
Mar 11, 2024	stein jeffrey	sold (taxes)	-39,117	0.69	-56,692	president & ceo
Mar 11, 2024	sandison taylor	sold	-13,839	0.6698	-20,662	chief medical officer
Mar 11, 2024	ward shane	sold	-13,712	0.6698	-20,473	coo & clo
Sep 11, 2023	tari leslie	sold	-17,508	0.948	-18,469	chief scientific officer

Which funds bought or sold CDTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-100,473	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	-	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	100	736	-%
Apr 24, 2024	Spire Wealth Management	added	101	5,621	9,200	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	unchanged	-	-112	2,888	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	reduced	-1.67	8,729	71,349	-%
Apr 19, 2024	Legacy Wealth Asset Management, LLC	unchanged	-	3,780	27,600	0.01%
Apr 17, 2024	JEPPSON WEALTH MANAGEMENT, LLC	added	4.35	23,653	136,758	0.05%
Apr 16, 2024	Pure Financial Advisors, LLC	unchanged	-	1,449	10,580	-%
Apr 12, 2024	Pacifica Partners Inc.	unchanged	-	-213	5,947	-%

Are Funds Buying or Selling CDTX?

Are funds buying CDTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDTX

No. of Funds

Unveiling Cidara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	5.4%	4,998,161	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	1.4%	1,250,000	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	1.7%	1,546,745	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	5.4%	3,868,006	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	6.1%	4,367,464	SC 13G/A
Feb 15, 2022	lytton laurence w	2.5%	1,708,328	SC 13G/A
Feb 14, 2022	point72 asset management, l.p.	6.3%	4,200,000	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	7.9%	5,270,458	SC 13G
Feb 14, 2022	omega fund v, l.p.	1.8%	1,249,999	SC 13G/A
Feb 11, 2022	bb biotech ag	0.0%	0	SC 13G/A

Recent SEC filings of Cidara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	8-K	Current Report
Apr 24, 2024	8-K	Current Report
Apr 23, 2024	S-8	Employee Benefits Plan
Apr 22, 2024	10-K	Annual Report
Apr 22, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to Cidara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Cidara Therapeutics Inc News

Latest updates

Cidara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	38.3%	17,583,000	12,718,000	7,614,000	25,990,000	10,219,000	40,744,000	6,216,000	7,109,000	7,225,000	7,076,000	32,863,000	2,408,000	3,729,000	2,416,000	3,392,000	2,530,000	1,815,000	19,100,000
Operating Expenses	11.2%	23,657,000	21,273,000	20,445,000	23,013,000	23,486,000	25,821,000	19,329,000	25,370,000	23,995,000	25,112,000	22,090,000	20,630,000	25,277,000	19,945,000	21,603,000	17,091,000	15,895,000	16,072,000
S&GA Expenses	-100.0%	-	3,556,000	3,310,000	4,298,000	3,428,000	5,780,000	4,074,000	5,204,000	4,982,000	4,607,000	4,370,000	4,781,000	4,148,000	3,687,000	3,969,000	4,095,000	4,405,000	4,573,000
R&D Expenses	-11.4%	15,352,000	17,330,000	17,135,000	18,715,000	20,058,000	20,041,000	15,255,000	20,166,000	19,013,000	20,505,000	17,720,000	15,849,000	21,129,000	16,258,000	17,634,000	12,996,000	11,490,000	11,499,000
EBITDA Margin	-88.5%	-0.61	-0.32	-0.28	-0.35	-0.46	-0.69	-1.53	-0.78	-0.85	-1.55	-1.73	-5.98	-5.91	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	2,000	13,000	25,000	38,000	51,000	64,000	75,000	88,000	102,000	116,000	139,000	144,000	157,000
Income Taxes	-72.2%	64,000	230,000	100,000	-	272,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	30.2%	-5,547,000	-7,942,000	-12,208,000	-	-13,105,000	14,978,000	-13,119,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-87.8%	-0.61	-0.32	-0.28	-0.36	-0.46	-0.69	-1.54	-0.78	-0.86	-1.57	-1.74	-6.04	-5.98	-	-	-	-	-
Net Income	31.3%	-5,611,000	-8,172,000	-12,357,000	3,209,000	-13,377,000	14,978,000	-13,119,000	-18,281,000	-16,803,000	-18,083,000	10,711,000	-18,292,000	-21,634,000	-17,632,000	-18,306,000	-14,539,000	-14,023,000	3,039,000
Net Income Margin	33.9%	-0.36	-0.54	-0.09	-0.10	-0.46	-0.54	-2.40	-0.78	-0.86	-1.03	-1.13	-6.35	-5.98	-	-	-	-	-
Free Cashflow	-633.0%	-12,900,000	-1,760,000	2,715,000	-10,992,000	-21,011,000	27,964,000	-11,852,000	-23,692,000	-14,907,000	-11,984,000	3,423,000	-1,805,000	-11,128,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.6%	67.00	63.00	68.00	82.00	48.00	67.00	40.00	55.00	75.00	51.00	64.00	54.00	60.00	64.00	73.00	84.00	69.00	82.00	52.00	64.00	79.00
Current Assets	5.5%	61.00	58.00	62.00	79.00	45.00	64.00	37.00	52.00	72.00	47.00	61.00	51.00	57.00	60.00	70.00	81.00	66.00	77.00	48.00	60.00	77.00
Cash Equivalents	-26.5%	36.00	49.00	50.00	48.00	33.00	53.00	25.00	38.00	62.00	40.00	53.00	49.00	43.00	54.00	64.00	74.00	60.00	74.00	45.00	57.00	75.00
Inventory	147.1%	6.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.0%	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00
Liabilities	35.7%	75.00	55.00	53.00	55.00	50.00	58.00	47.00	50.00	54.00	52.00	48.00	52.00	50.00	34.00	32.00	30.00	31.00	33.00	20.00	20.00	20.00
Current Liabilities	89.3%	67.00	36.00	31.00	36.00	30.00	33.00	31.00	32.00	34.00	33.00	34.00	40.00	39.00	34.00	32.00	30.00	30.00	32.00	19.00	19.00	20.00
Shareholder's Equity	-202.1%	-8.21	8.00	15.00	27.00	-14.44	9.00	-18.54	5.00	22.00	-	16.00	2.00	11.00	30.00	41.00	54.00	38.00	49.00	32.00	44.00	59.00
Retained Earnings	-4.0%	-441	-424	-416	-403	-406	-393	-408	-395	-377	-360	-342	-353	-334	-313	-295	-277	-259	-245	-248	-235	-218
Additional Paid-In Capital	0.2%	433	432	432	431	404	403	401	400	399	359	358	355	345	343	337	331	298	295	281	279	278
Shares Outstanding	0.3%	91.00	90.00	90.00	5.00	4.00	70.00	69.00	3.00	3.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	100	-	-	-	33.00	-	-	-	98.00	-	-	-	151	-	-	-	44.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-678.6%	-12,722	-1,634	2,822	-10,898	-21,002	27,973	-11,836	-23,608	-14,907	-11,972	3,440	-1,793	-11,128	-14,083	-14,072	-15,128	-15,197	16,619	-12,808	-17,146	-13,666
Share Based Compensation	4.3%	830	796	795	640	673	843	678	1,338	1,363	901	871	879	847	1,002	995	1,246	1,023	1,509	1,257	1,284	1,364
Cashflow From Investing	-41.3%	-178	-126	-107	-94.00	-9.00	-9.00	-16.00	-84.00	-	-12.00	-17.00	-12.00	-	-54.00	-96.00	-36.00	-	-	-26.00	-9.00	4,460
Cashflow From Financing	-	8.00	-	-261	26,237	664	107	-1,111	-611	36,875	-810	887	7,645	409	3,720	3,939	29,210	1,641	12,632	-	-	-12.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

CDTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration revenue	$ 11,250	$ 7,497	$ 26,107	$ 40,744	$ 6,216	$ 7,269	$ 33,604	$ 13,485	$ 44,854	$ 54,229	$ 59,570	$ 64,448
Product revenue	1,468			0					1,468	0	4,335	0
Total revenues	12,718	7,497	26,107	40,744	6,216	7,269	33,604	13,485	46,322	54,229	63,905	64,448
Operating expenses:
Cost of product revenue	387			0					387	0	1,523	0
Research and development	17,389	17,556	18,869	20,283	16,630	20,381	36,425	37,011	53,814	57,294	68,532	77,405
Selling, general and administrative	4,432	4,039	4,457	6,270	5,339	5,342	8,496	10,681	12,928	16,951	18,333	20,546
Total operating expenses	22,208	21,595	23,326	26,553	21,969	25,723	44,921	47,692	67,129	74,245	88,388	97,951
Loss from operations	(9,490)	(14,098)	2,781	14,191	(15,753)	(18,454)	(11,317)	(34,207)	(20,807)	(20,016)	(24,483)	(33,503)
Other income, net:
Interest income, net	613	623	232	55	(6)	(20)	855	(26)	1,468	29	1,995	191
Total other income, net	613	623	232	55	(6)	(20)	855	(26)	1,468	29	1,995	191
Loss before income tax expense	(8,877)	(13,475)		14,246	(15,759)		(10,462)	(34,233)	(19,339)	(19,987)	(22,488)	(33,312)
Income tax expense	(230)	(149)		0	0		(149)	0	(379)	0	(443)	(272)
Net loss and comprehensive loss	(9,107)	(13,624)	3,013	14,246	(15,759)	(18,474)	(10,611)	(34,233)	(19,718)	(19,987)	(22,931)	(33,584)
Net loss and comprehensive loss	$ (9,107)	$ (13,624)	$ 3,013	$ 14,246	$ (15,759)	$ (18,474)	$ (10,611)	$ (34,233)	$ (19,718)	$ (19,987)	$ (22,931)	$ (33,584)
Basic net loss per common share (USD per share)	$ (0.10)	$ (0.15)	$ 0.03	$ 0.16	$ (0.23)	$ (0.27)	$ (0.13)	$ (0.50)	$ (0.23)	$ (0.29)	$ (0.26)	$ (0.48)
Diluted net loss per common share (USD per share)	$ (0.10)	$ (0.15)	$ 0.03	$ 0.16	$ (0.23)	$ (0.27)	$ (0.13)	$ (0.50)	$ (0.23)	$ (0.29)	$ (0.26)	$ (0.48)
Shares used to compute basic net loss per common share (in shares)	90,287,441	90,115,859	78,640,086	70,217,985	69,133,700	68,138,116	84,409,667	68,638,651	86,390,446	69,170,865	87,427,439	69,857,698
Shares used to compute diluted net loss per common share (in shares)	90,287,441	90,115,859	101,189,396	88,592,568	69,133,700	68,138,116	84,409,667	68,638,651	86,390,446	69,170,865	87,427,439	69,857,698

CDTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 35,778	$ 48,670	$ 50,430	$ 47,976	$ 32,731	$ 53,078	$ 24,637	$ 36,488
Accounts receivable	16,246	3,178	5,483	26,121	5,833	5,042	4,833	8,783
Inventory	6,097	2,901	2,388		0	0	0
Prepaid expenses and other current assets	2,734	3,712	4,373	5,711	6,530	5,779	6,706	5,254
Total current assets	60,855	58,461	62,674	79,808	45,094	63,899	36,546	52,007
Property and equipment, net	557	580	297	270	222	173	201	239
Finance lease right-of-use asset, net	782				0
Operating lease right-of-use asset	3,788	4,050	4,307	836	1,099	1,354	1,602	1,846
Other assets	1,048	1,053	1,061	1,061	1,072	1,295	1,013	1,019
Total assets	67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
Current liabilities:
Accounts payable	3,772	3,661	1,899	4,026	1,447	4,244	3,091	2,861
Accrued liabilities	14,177	11,772	10,022	9,108	7,672	8,162	8,567	9,954
Accrued indirect tax liabilities	18,040	14,689	13,431	11,795	11,534	11,314	10,582	7,942
Accrued compensation and benefits	5,034	4,457	3,582	5,843	4,922	4,117	3,464	3,079
Current contract liabilities	25,095	14,679	14,975	15,790	14,614	15,249	14,730	14,260
Current portion of finance lease liability	218				0
Current portion of operating lease liability	1,082	970	861	920	1,211	1,169	1,129	1,090
Total current liabilities	67,418	50,228	44,770	47,482	41,400	44,255	41,933	40,667
Long-term contract liabilities	4,245	16,504	17,551	19,386	20,525	24,398	15,351	17,229
Long-term finance lease liability	575				0
Long-term operating lease liability	3,002	3,306	3,601	0	0	315	621	920
Total liabilities	75,240	70,038	65,922	66,868	61,925	68,968	57,905	58,816
Commitments and contingencies
Stockholders’ deficit:
Preferred stock
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 90,601,999 shares issued and outstanding at December 31, 2023; 72,470,440 shares issued and outstanding at December 31, 2022	9	9	9	9	7	7	7	7
Additional paid-in capital	433,212	432,315	431,519	430,585	404,055	402,649	400,599	399,678
Accumulated deficit	(441,431)	(438,218)	(429,111)	(415,487)	(418,500)	(404,903)	(419,149)	(403,390)
Total stockholders’ deficit	(8,210)	(5,894)	2,417	15,107	(14,438)	(2,247)	(18,543)	(3,705)	$ 13,104
Total liabilities and stockholders’ deficit	67,030	64,144	68,339	81,975	47,487	66,721	39,362	55,111
Series X Convertible Preferred Stock
Stockholders’ deficit:
Preferred stock	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0

About Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CEO	Dr. Jeffrey L. Stein Ph.D.
WEBSITE	cidara.com
INDUSTRY	Biotechnology
EMPLOYEES	73

Cidara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cidara Therapeutics Inc? What does CDTX stand for in stocks?

CDTX is the stock ticker symbol of Cidara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cidara Therapeutics Inc (CDTX)?

As of Fri Apr 26 2024, market cap of Cidara Therapeutics Inc is 1.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDTX stock?

You can check CDTX's fair value in chart for subscribers.

What is the fair value of CDTX stock?

You can check CDTX's fair value in chart for subscribers. The fair value of Cidara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cidara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cidara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CDTX is over valued or under valued. Whether Cidara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cidara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDTX.

What is Cidara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CDTX's PE ratio (Price to Earnings) is -50.25 and Price to Sales (PS) ratio is 18.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDTX PE ratio will change depending on the future growth rate expectations of investors.